Exicure to Present at the Benzinga Healthcare Small Cap Conference
September 23 2021 - 7:00AM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced that CEO David Giljohann will present
at the Benzinga Healthcare Small Cap Conference on Thursday,
September 30, 2021, at 3:20 PM ET.
Exicure management will be available for one-on-one meetings to
be held throughout the conference. Investors can register to
receive a free spectator pass for the event here.
The conference live stream will be available here. Replays of
the presentation will be available on Exicure’s website following
the presentation.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on its
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA. www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210923005020/en/
Media: Karen Sharma MacDougall 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024